

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.
Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hope’s exceptional cancer expertise.
A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.
Pay Rate: $38.96 - $132.16 per hour
Join the forefront of groundbreaking research at the Beckman Research Institute of City of Hope, where we're changing lives and making a real difference in the fight against cancer, diabetes, and other life-threatening illnesses. Our dedicated and compassionate faculty and staff are driven by a common mission: Contribute to innovative approaches in predicting, preventing, and curing diseases, shaping the future of medicine through cutting-edge research.
A Staff Scientist position is available in the Vaccine Research Laboratory of Dr. Don Diamond in the Department of Hematology & Hematopoietic Cell Transplantation of the City of Hope. The position is available as part of a multi-disciplinary research team tasked to develop a neoantigen-based cancer vaccine for clinical use. We received favorable comments from the FDA on our Pre-IND submission utilizing a highly efficient and fully synthetic poxvirus-vectored vaccine platform that has already been derisked by its use in Phase 2 clinical trials as a Covid-19 vaccine (see NCT04977024, NCT05672355, and NCT04639466).
Please refer to these publications for further background: doi:10.3390/vaccines11091492, PMC7705736, PMC8906816, PMID33257686, PMID31739399 describing the platform and earlier publications using a p53-expressing MVA as a clinical therapeutic in cancer patients (10.1158/2767-9764.CRC-23-0394, PMC8802616, PMC5856606, and PMC5706612).
As a successful candidate, you will:
Your qualifications should include:
City of Hope is an equal opportunity employer.
To learn more about our Comprehensive Benefits, please CLICK HERE.